Travere Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US89422G1076 (TVTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Read full profile
Fundamentals
- Net revenue
€284.77M - Gross margin
92.7% - EBIT
-€144.55M - EBIT margin
-50.8% - Net income
-€144.20M - Net margin
-50.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
|
|
|
|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
| Andreas Halvorsen |
|
|
|
Sell |
Earnings Calls
Latest earnings call: August 6, 2025 (Q2 2025)